Today Johanna Snellström presented her Diploma Work entitled “Quantification of Cytotoxic Drugs in Human Blood: Method Development in Personalized Medicine”, performed at MetaSafe AB as a collboration between AdductAnalys (Supervisor Andreas Rydén) and MetaSafe (Co-supervisor Göran Eklund).
Congratulations to Johanna Snellström for a perfect Diploma Work presentation today at Department of Environmental Science and Analytical Chemistry, Stockholm University.
2 June, 2016
It is a great pleasure to present our latest addition to the team, Anja Ekdahl, PhD.
Anja Ekdahl received an M.S. in Analytical Chemistry in 1991 and a PhD in Analytical Chemistry in 1997 from Gothenburg University (Thesis: On the origin and assessment of biogenic halocarbons). She did two years of post doc studies at the Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, UC San Diego, California US. In 2000 she joined AstraZeneca Gothenburg (former Mölndal) as a biotransformation scientist. The biotransformation support to projects within AZ has included profiling and identification of metabolites from in vitro and in vivo studies in both animals and humans, MIST evaluations and regulatory reporting. Her long experience in biotransformation studies in development is rare and she is a valuable addition to the team.
MetaSafe further strengthens the team – Biotransformation Specialist with 15 years experience in drug development starts 1st of June. Presentation will come.
9 March, 2016
Cross species comparison, stability investigations, SAD Met ID are examples of ongoing studies at MetaSafe
9 February, 2016
MetaSafe Strengthens the Team
18 November, 2015
We are delighted to announce the appointment of our new team member Dr. Magnus Halldin. Magnus is now appointed as Scientific Advisor for MetaSafe in the DMPK (ADME) area in which Magnus possesses 30 years of experience.
Magnus has a Master’s degree in Pharmacy from School of Pharmacy, University of Uppsala, Uppsala 1977 and a PhD in Pharmacognosy (Thesis: Biotransformation of Tetrahydrocannabinol in Man and Animal) from University of Uppsala, 1982.
After postdoctoral studies at School of Pharmacy, University of California, San Francisco, USA, Magnus Halldin joined Astra (AstraZeneca) in 1985, where he up to 2013 held various line, project and scientific management positions in the company. Magnus also had a scientific DMPK advisory role on numerous global scientific committees and knowledge groups, and in-licensing and due diligence opportunities within both Discovery and Development.
His appointment is a valuable addition to the team and a perfect complement to our analytical service within the DMPK area in both discovery and development.